Wavefront-guided LASIK for Myopia Using the LADAR CustomCornea and the VISX CustomVue

Abstract

To evaluate the objective and subjective visual outcomes and refractive results of wavefront-guided LASIK with LADAR CustomCornea and VISX CustomVue. This prospective randomized single-institution multisurgeon study comprised 100 eyes of 58 patients (50 eyes on each laser platform). Uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), and manifest refraction were measured postoperatively at 1 day, 1 week, 1 month, and 3 months. Contrast sensitivity, higher order aberrations measurement, and a subjective vision questionnaire were performed preoperatively and at 3 months. Preoperatively, the CustomCornea group had a mean manifest sphere of -3.58 +/- 1.61 diopters (D) (range: -0.50 to -7.25 D), cylinder of +0.64 +/- 0.45 D (range: 0 to +1.75 D), and manifest refractive spherical equivalent (MRSE) of -3.26 +/- 1.56 D. The CustomVue group had a manifest sphere of -4.00 +/- 1.69 D (range: -1.50 to -7.50 D), cylinder of +0.60 +/- 0.52 D (range: 0 to +2.00 D), and MRSE of -3.70 +/- 1.64 D. At 3 months, 94% of CustomCornea eyes and 84% of CustomVue eyes had UCVA > or = 20/20 (P = .20). Twenty-four percent of CustomVue eyes and 22% of CustomCornea eyes gained 1 line of BSCVA. In both groups, 96% of eyes were within 0.50 D of emmetropia. Mean CustomCornea glare contrast sensitivity improved (P = .04) whereas more eyes improved than worsened in both groups. Spherical aberration and total higher order aberrations increased, and trefoil decreased in both groups. A decrease in coma was noted in 70% of CustomCornea eyes. Wavefront-guided LASIK with both platforms is safe, effective, and delivers excellent visual results. CustomCornea improves contrast sensitivity under glare conditions.